Julie Maréchal-Jamil, director of biosimilars policy and science at Medicines for Europe, describes opportunities for biosimilars in the year ahead.
Transcript
This year for us is very special because we have European elections. It's a time when the political agenda gets quite reset for another 5 years, so it's very important and for us, it's important that the parliament that will be elected in May and then the European Commission that will be formed then in the fall all have a strategic agenda for health. That's very important for us, but more importantly that they have a reserved place for biosimilars to play an important role in that agenda.
Two points: I think, in Europe, there's a big focus on reducing inequalities in access, and biosimilars are very obvious and readily available to contribute to meeting that objective, so I think we're calling on the institution this year [in a very] big [way] to to have that strategic inclusion of biosimilars in meeting their health objectives.
The other bit is more on the industrial side of things, where biosimilars were born here in Europe because of how the system was set up early on, their legal framework and everything, but we haven't fared very well in manufacturing capability and know-how; that really needs to be nurtured because the the needs are growing in Europe and elsewhere, and I think it's important that we nurture that for the long-term.
So 2 agendas: one more on the equity, creating greater equity, and the other more on the industrial policy side. So this is our big agenda for 2019.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.